Incyte

3 results

Eli Lilly: has suffered some recent setbacks with the US Food and Drug Administration. Photograph: Michael Nagle/Bloomberg

Eli Lilly and Co reported a bigger-than-expected quarterly adjusted profit as the drugmaker benefited from higher demand for its newer products includ(...)

Baricitinib had been expected to generate more than $2bn in peak annual sales by taking a share of the lucrative rheumatoid arthritis market.  Photograph: PA Wire

Investors wiped a combined $6 billion (€5.6bn) from the market value of Eli Lilly and its biotech partner Incyte after the US medicines regulator reje(...)

Wall Street was slightly higher in volatile trading on Thursday as a decline in biotech stocks offset gains in energy shares.

Crude oil prices rose on Thursday to their highest in three weeks on hopes for a pact among oil producers to cut output, while the dollar slipped on b(...)